Summary
The pigmented neurons of the substantia nigra (SN) are typically lost in Parkinson’s disease: however the possible relationship between neuronal vulnerability and the presence of neuromelanin (NM) has not been elucidated. Early histological studies revealed the presence of increasing amounts of NM in the SN with aging in higher mammals, showed that NM granules are surrounded by membrane, and comparatively evaluated the pigmentation of SN in different animal species. Histochemical studies showed the association of NM with lipofuscins. However, systematic investigations of NM structure, synthesis and molecular interactions have been undertaken only during the last decade. In these latter studies, NM was identified as a genuine melanin with a strong chelating ability for iron and affinity for compounds such as lipids, pesticides, and MPP+. The affinity of NM for a variety of inorganic and organic toxins is consistent with a postulated protective function for NM. Moreover, the neuronal accumulation of NM during aging, and the link between its synthesis and high cytosolic concentration of catechols suggests a protective role. However, its putative neuroprotective effects could be quenched in conditions of toxin overload.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams JD, Odunze IN (1991) Biochemical of 1-methyl-4-phenyl-1,2,3,5-tetrahydropyridine toxicity: could oxidative stress be involved in the brain? Biochem Pharmacol 41: 1099–1105
Adler A (1942) Melanin pigment in the central nervous system vertebrates. J Comp Neurol 76: 501
Aime S, Fasano M, Bergamasco B, Lopiano L, Valente G (1994) Evidence for a glicid-lipid matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra. J Neurochem 62: 369–371
Barden H (1969) The histochemical relationship of neuromelanin and lipofuscin. J Neuropathol Exp Neurol Baltimore 28: 419–441
Barden H (1975) Histochemical relationship and nature of neuromelanin. Aging 1: 79–117
Bazelon M, Fenichel GM (1967) Studies on neuromelanin I. A melanin system in the human adult brainstem. Neurology 17: 512–519
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455
Bogerts B (1981) A brainstem atlas of catecolaminergic neurons in man, using melanin as natural marker. J Comp Neurol 197: 63–80
Bridelli MG, Tampellini D, Zecca L (1999) The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. Febs Lett 457: 18–22
Carstam R, Brink C, Hindemint-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of substantia nigra. Biochim Biophys Acta 1097: 152–160
Cheng J, Moss SC and Eisner M (1994) X-Ray characterization of melanins-II. Pigment Cell Res 7: 263–273
Cotzias GC, Papavasidou PS, Van Woert MH, Sakamoto A (1964) Melanogenesis and extrapiramidal disorders. Fed Proc 233: 713–718
Cowen D (1986) The melanoneurons of the human cerebellum (nucleus pigmentosus cerebellaris) and homologues in the monkey. J Neuropathol Exp Neurol 45: 205–221
Cozzi B, Tozzi F (1985) A spectroscopy study of the equine brain melanins. Archo Vet It, Milano 36: 34–40
Cozzi B, Pellegrini M, Droghi A (1988) Neuromelanin in the substantia nigra of adult horses. Anat Anz Jena 166: 53–61
Crippa R, Wang QJ, Eisner M, Moss SC, Zecca L, Zachack P, Gog T (1996) Structure of human neuromelanin by X-Ray diffraction: comparison with synthetics. Pigment Cell Res 5: 72
D’Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231: 987–989
DeMattei M, Levi AC, Fariello RG (1986) Neuromelanic pigment in substantia nigra neurons of rats and dogs. Neurosci Lett 72: 37–42
Dexter DT, Wells FR, Lees AJ, Jenner I, Marsden CD (1989) Increased nigral iron content and alteration in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52:1830–1836
Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75: 2583–2589
Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson’s disease. J Neuropathol Exp Neurol 24: 398–414
Enochs WS, Nilges MJ, Swartz HM (1993) Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J Neurochem 61: 68–79
Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM (1994) The roles of neuromelanin binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson’s disease: a hypothesis. J Neural Transm [PD-Sect] 7: 83–100
Fenichel GM, Bazelon M (1968) Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology 18: 817–820
Foley JM, Baxter D (1958) On the nature of pigment granules in the cell of the locus coeruleus and substantia nigra. J Neuropathol Exp Neurol 7: 586–598
Fornsted B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivates of dopamine, dopa and dopac in brains of eight mammalian species. Neuropharmacology 25: 451–454
Galazka-Friedman J, Bauminger ER, Friedman A, Barcikowska M, Hechel D, Nowik I (1996) Iron in parkinsonian and control substantia nigra, a Mossbauer spectroscopy study. Mov Disord 11: 8–16
Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103: 987–1041
Gerlach M, Trautwein AX, Zecca L, Youdim MBH, Riederer P (1995) Mössbauer spectroscopic studies of human neuromelanin isolated from the substantia nigra. J Neurochem 65: 923–926
Gibb WRG (1992) Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson’s disease. Brain Res 581: 283–291
Gibb WRG, Fearnley JM, Lees AJ (1990) The anatomy of the human substantia nigra in relation to selective neuronal vulnerability. In: Streifler MB, Korczyn AD, Melamed E and Youdim MBH (eds) Advances in neurology, vol 53. Parkinson’s disease: anatomy, pathology and therapy. Raven Press, New York, pp 31–34
Good PF, Olanow CW, Perl DP (1992) Neuromelanin containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson’s disease: a LAMMA study. Brain Res 593: 343–346
Graham DG (1979) On the origin and significance of neuromelanin. Arch Pathol Lab Med (July) 103: 359–362
Haavik J, Almas B, Fiatmark T (1997) Generation of reactive oxygen species by tyrosine hydroxilase: a possible contribution to the degeneration of dopaminergic neurons. J Neurochem 68(1): 328–332
Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64: 919–924
Hirosawa K (1968) Electron microscopic studies on pigment granules in the substantia nigra and locus coeruleus of the Japanese monkey (macaca fuscata yukui). Z Zeilforsch 88: 187–203
Höck A, Demmel U, Schicha H, Kasperek K, Feinendegen LE (1975) Trace element concentration in human brain. Brain 98: 49–64
Hornykiewicz O (1986) Biochemical pathophysiology of Parkinson’s disease. Adv Neurol 45: 19–22
Ikemoto K, Nagatsu I, Ito S, King RA, Nishimura A, Nagatsu T (1998) Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? Neurosci Lett 253: 198–200
Jellinger K, Kienzl E, Rumpelmaier G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168–1171
Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson’s disease related to their neuromelanin content? J Neurochem 59: 1080–1089
Kropf AJ, Bunker BA, Eisner M, Moss SC, Zecca L, Stroppolo A, Crippa PR (1998) X-ray absorption fine-structure spectroscopy studies of iron sites in synthetic and natural neuromelanin. Biophys J 75: 3135–3142
Kubis N, Faucheux BA, Ransmary G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw J-J, Agid Y, Hirsch EC (2000) Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123: 366–373
Langston JW, Irwin I (1986) MPTP: current concepts and controversies. Clin Neuropharmacol 9: 485–507
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to product of meperidine-analog synthesis. Science 219: 979–980
Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of human years after 1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598–605
Lindquist NG, Larsson BS, Lydén-Sokolowski A (1988) Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci Lett 93: 1–6
Lopiano L, Chiesa M, Digilio G, Giraudo S, Bergamasco B, Torre E, Fasano M (2000) Q-band EPR investigations of neuromelanin in control and Parkinson Disease patients. Biochim Biophys Acta 1500(3): 306–312
Mann DMA, Yates PO (1974) Lipoprotein pigments-their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 97: 489–498
Mann DM, Yates PO (1983) Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mech Ageing Dev 21: 193–203
Markesbery WR, Ehmann WD, Alauddin M, Hossain TI (1984) Brain trace element in aging. Neurobiol Aging 5: 19–28
Marsden CD (1961) Pigmentation in the nuculeus substantiae nigrae of mammals. J Anat 95:1080–1089
Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, Wistow GJ, Hearing VJ (1999) Enzyme activity of macrofage migration inhibitory factor toward oxidized catecholamines. J Biol Chem 274: 3268–3271
Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson’s Disease. J Neurochem 64: 1645–1654
McGeer PL, McGeer EG, Suzuki JS (1977) Aging and extrapyramidal functions. Arch Neurol 34: 33–35
McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer disease brains. Neurology 38(8): 1285–1291
Moses HL, Ganote CE, Beaver DL, Shuffman SS (1966) Light and electron microscopic studies of pigment in human and rhesus monkey substantia nigra and locus coeruleus. Anat Rec 155: 167–184
Muthane UB, Yasha TC, Shankar SK (1998) Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 43: 283–287
Odh G, Carstam R, Paulson J, Wittbjer A, Rosengren E, Rosman H (1994) Neuromelanin of the human substantia nigra: a mixed type melanin. J Neurochem 62: 2030–2036
Okun MR (1997) The role of peroxidase in neuromelanin synthesis: a review. Physiol Chem Phys and Med NMR 29: 15–22
Pakkenberg B, Moller A, Gundersen HJG, Mouritzen DA, Pakkenberg H (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54: 30–35
Rosengren E, Linder-Eliasson E, Carlsson A (1985) Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63: 247–253
Salazar M, Sokoloski TD, Patil PN (1978) Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed Proc 37: 2403–2407
Sanchez-Ferrer A, Rodriguez-Lopez JN, Garcia-Canovas F, Garcia-Carmona F (1995) Tyrosinase: a review of its mechanism. Biochim Biophys Acta 1247: 1–11
Schrerer HJ (1939) Melanin pigmentation of the substantia nigra in primates. J Comp Neurol 71: 91
Shima T, Sarna T, Stroppolo A, Gerbasi R, Swartz HM, Zecca L (1997) Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 23: 110–119
Singer TP, Castagnoli N, Ramsay RR, Trevor AJ (1987) Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,5-tetraydropiridine. J Neurochem 49: 1–8
Smythies J (1996) On the function of neuromelanin. Proc Roy Soc Lond B 263: 487–489
Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in Substantia nigra zone compacta of parkinsonian brain. J Neurochem 56: 978–982
Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karetekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci 97(22): 11869–11874
Swartz HM, Sarna T, Zecca L (1992) Modulation by neuromelanins of the availability and reactivity of metal ions. Ann Neurol 32: S69–S75
Tief K, Schmidt A, Beerman F (1998) New evidence for presence of tyrosinase in substantia nigra, forebrain, and midbrain. Mol Brain Res 53: 307–310
Van Woert MH, Ambani LM (1974) Biochemistry of neuromelanin. Adv Neurol 5: 215–223
Wakamatsu K, Ito S and Nagatsu T (1991) Cysteinyldopamine is not incorporated into neuromelanin. Neurosci Lett 131: 57–60
Xu Y, Stokes AH, Freeman WM, Kumer S, Vogt B, Vrana K (1997) Tyrosinase mRNA is expressed in human substantia nigra. Mol Brain Res 45: 159–162
Zareba M, Bober A, Korytowski W, Zecca L, Sarna T (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim Biophys Acta 1271: 343–348
Zecca L, Swartz HM (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin. J Neural Transm [PD-Sect] 5: 203–213
Zecca L, Mecacci C, Seraglia R, Parati E (1992) The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta 1138: 6–10
Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E (1994) Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 62: 1097–1101
Zecca L, Shima T, Stroppolo A, Goj C, Battiston GA, Gerbasi R, Sarna T, Swartz HM (1996) Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neurosci 73: 407–415
Zecca L, Costi P, Mecacci C, Ito S, Terreni T, Sonnino S (2000) The interaction of human substantia nigra neuromelanin with lipids and peptides. J Neurochem 74: 1758–1765
Zecca L, Gallorini L, Schünemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin in substantia nigra of normal subjects at different ages. Consequences for iron storage and neurodegenerative disorders. J Neurochem 76: 1766–1773
Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett 510: 216–220
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this paper
Cite this paper
Zecca, L. et al. (2003). The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. In: Horowski, R., et al. Advances in Research on Neurodegeneration. Journal of Neural Transmission. Supplementa, vol 65. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0643-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0643-3_8
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83907-2
Online ISBN: 978-3-7091-0643-3
eBook Packages: Springer Book Archive